| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
Faropenem medoxomil (Faropenem daloxate; Faropenem medoxil) is an orally bioactive beta-lactam antibiotic of the penem class. It is a prodrug of Faropenem. Faropenem medoxomil is the first oral penem in a new class of beta-lactam antibiotics. Faropenem medoxomil has excellent in vitro activity against Streptococcus pneumoniae, Haemophilus influenzae and other key pathogens implicated in acute bacterial rhinosinusitis.
| References |
|
|---|---|
| Additional Infomation |
Faropenem ester is an organic nitrogen and organic oxygen compound whose function is related to α-amino acids. Faropenem ester is an ester prodrug derivative of the β-lactam antibiotic faropenem. The faropenem prodrug form significantly improves oral bioavailability and allows for higher drug concentrations in vivo. Faropenem ester is a broad-spectrum antibiotic with high resistance to degradation by β-lactamases. It was jointly developed by Replidyne and Forest Laboratories. Faropenem ester is the daloxate prodrug form of faropenem, a penem antibiotic with a tetrahydrofuran substituent at the C2 position, exhibiting broad-spectrum antibacterial activity against a variety of Gram-positive and Gram-negative aerobic and anaerobic bacteria. Faropenem ester hydrolyzes in vivo, releasing active free acids. Compared to imipenem, faropenem has higher chemical stability and reduced effects on the central nervous system. Furthermore, faropenem is resistant to hydrolysis by a variety of β-lactamases. Drug Indications Faropenem has been investigated for the treatment of bacterial infections, bronchitis, otitis media, and pediatric diseases. Mechanism of Action Like other β-lactam antibiotics, faropenem exerts its effect by inhibiting bacterial cell wall synthesis. It inhibits the cross-linking between linear peptidoglycan polymer chains, the main components of the cell wall of Gram-positive bacteria. It exerts its effect by binding to and competitively inhibiting the transpeptidase (D-alanyl-alanine) used by bacteria in the synthesis of cross-linked peptidoglycan. Pharmacodynamics Faropenem has shown excellent in vitro activity against common respiratory pathogens, many aerobic Gram-positive bacteria, and anaerobes. Its activity against Gram-negative bacteria is more limited. In vivo data suggest that faropenem is effective in treating community-acquired infections, including uncomplicated skin and soft tissue infections; however, more data are needed to clarify faropenem's role in antimicrobial therapy.
|
| Molecular Formula |
C17H19NO8S
|
|---|---|
| Molecular Weight |
397.398
|
| Exact Mass |
397.083
|
| Elemental Analysis |
C, 51.38; H, 4.82; N, 3.52; O, 32.21; S, 8.07
|
| CAS # |
141702-36-5
|
| Related CAS # |
141702-36-5;16559-89-1;
|
| PubChem CID |
6918218
|
| Appearance |
Solid powder
|
| Density |
1.55 g/cm3
|
| Boiling Point |
622.3ºC at 760 mmHg
|
| Vapour Pressure |
4.3E-18mmHg at 25°C
|
| Index of Refraction |
1.642
|
| LogP |
0.825
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
775
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O=C(N1[C@@]2(SC([C@@H]3OCCC3)=C1C(OCC4=C(OC(O4)=O)C)=O)[H])[C@@H]2[C@H](O)C
|
| InChi Key |
JQBKWZPHJOEQAO-DVPVEWDBSA-N
|
| InChi Code |
InChI=1S/C17H19NO8S/c1-7(19)11-14(20)18-12(13(27-15(11)18)9-4-3-5-23-9)16(21)24-6-10-8(2)25-17(22)26-10/h7,9,11,15,19H,3-6H2,1-2H3/t7-,9-,11+,15-/m1/s1
|
| Chemical Name |
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (5R,6S)-6-((R)-1-hydroxyethyl)-7-oxo-3-((R)-tetrahydrofuran-2-yl)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
|
| Synonyms |
A0026; A-0026; A 0026; Faropenem medoxomil; Faropenem daloxate; Faropenem medoxil.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~251.64 mM )
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.29 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.29 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.29 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (6.29 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5164 mL | 12.5818 mL | 25.1636 mL | |
| 5 mM | 0.5033 mL | 2.5164 mL | 5.0327 mL | |
| 10 mM | 0.2516 mL | 1.2582 mL | 2.5164 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
